Please assess the completion status of the following clinical trial:

Trial Title: Effect of IV Vitamin C, Thiamine, and Steroids on Mortality of Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted to medical intensive care unit (MICU) for less than 24 hours, who are hypotensive despite a fluid bolus of 30 mL/kg and who are requiring pressors to keep MAP \> 65 of at least 5 mcg/min of levophed or equivalent and whose shock is clinically suspected to be secondary to sepsis.~* In addition, stress dose corticosteroids, hydrocortisone 50mg IV Q6hrs, will have to have been started or intended to be started.~Exclusion Criteria:~* Contraindication to corticosteroids, thiamine, or vitamin C~* Treating physician opposed to administering corticosteroids to the patient~* Age \< 18 years~* Pregnancy~* DNR/DNI/limitations of care~* Patients with a fatal underlying disease who are unlikely to survive to hospital discharge~* Patients with a primary admitting diagnosis of an acute cerebral vascular event, acute coronary syndrome, active gastrointestinal bleeding, burn or trauma~* Requirement for immediate surgery~* Patients with HIV and a CD4 \< 50 mm2~* Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency.8~* Involvement in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin C and Thiamine (Type: EXPERIMENTAL): IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
- Placebo (Type: PLACEBO_COMPARATOR): 50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.

Based on this trial design, predict the completion outcome and termination type (if applicable).